ReviewBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2025
Tumor-derived extracellular vesicles: Bridging communication and next-generation theranostics.
Review in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Extracellular Vesicles in Diffuse Midline Glioma: Emerging Mediators of Radiation Response and Therapeutic Resistance.Cancers · 2026Review
- A MUC1-ALIX complex regulates extracellular vesicle cargo loading with activated SRC to enhance pancreatic cancer progression.Cancer letters · 2026Article
- Extracellular vesicles in colorectal cancer: immunomodulation, diagnostics, and therapeutic perspectives.Medical oncology (Northwood, London, England) · 2026Review
- Exosomes as Pivotal Mediators of Tumor-Immune Communication: Implications for Immunotherapy and Liquid Biopsy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cancer remains one of the leading causes of mortality worldwide, and despite advancements in therapeutic strategies-including chemotherapy, radiotherapy, immunotherapy, surgery, hormone therapy, and targeted therapy-a definitive cure remains elusive. In recent years, tumor-derived extracellular vesicles (TD-EVs) have garnered attention due to their critical roles in tumorigenesis, angiogenesis, and metastasis. Generated via biogenesis pathways involving the endosomal sorting complex required for transport (ESCRT), TD-EVs facilitate diverse mechanisms that promote tumor growth and survival. These include the induction of epithelial-mesenchymal transition (EMT), stimulation of angiogenesis, suppression of natural killer (NK) and T cell activity, promotion of M2 macrophage polarization, and facilitation of metastasis. Beyond their tumor-promoting functions, TD-EVs also hold promise as diagnostic and therapeutic tools. For example, EV PD-L1 has emerged as a biomarker for the liquid biopsy, reflecting tumor immune evasion, while engineered TD-EVs loaded with therapeutic cargos such as siRNAs or chemotherapeutic agents have shown potential in targeted tumor delivery. Their presence in bodily fluids and selective enrichment of tumor-specific cargo position them as valuable candidates for liquid biopsy applications, enabling non-invasive monitoring of disease progression and treatment responses. Furthermore, engineered TD-EVs are being explored as delivery systems for chemotherapeutics, RNA interference molecules, and gene-editing tools. Despite these advances, different challenges hinder the clinical translation of TD-EV-based applications. These include the heterogeneity of EV populations, lack of standardized isolation and characterization protocols, and difficulty in distinguishing TD-EVs from normal EVs in complex biological samples. Key obstacles also include the pronounced heterogeneity of EV populations and the lack of standardized isolation and characterization protocols. This review explores the multifaceted roles of TD-EVs in cancer biology and their potential utility in diagnosis, prognosis, and therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.